Filing Flows › Emergent BioSolutions (EBS) › R&D spending
Emergent BioSolutions (EBS) R&D spending by quarter
Emergent BioSolutions' R&D spending was $9.4M in Q3 2026 (third quarter 2026), +2% from Q2 2026. Over the last 7 quarters it ranged from $9.2M (Q2 2026) to $15.1M (Q1 2025).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $9.4M | +2% | -30% |
| Q2 2026 | $9.2M | -12% | -26% |
| Q1 2026 | $10.5M | -13% | -30% |
| Q4 2025 | $12.1M | -10% | — |
| Q3 2025 | $13.5M | +8% | — |
| Q2 2025 | $12.5M | -17% | — |
| Q1 2025 | $15.1M | — | — |
Q3 2026 at a glance
Emergent BioSolutions, Q3 2026: revenue $110M (-52% year over year), operating margin -33.9%, net loss $32.7M, operating cash flow $100M. The chart follows the revenue to costs, profit and cash.
Questions
What is Emergent BioSolutions' R&D spending?
Emergent BioSolutions' R&D spending was $9.4M in Q3 2026 (third quarter 2026), +2% from Q2 2026.
How has Emergent BioSolutions' R&D spending changed?
Over the last 7 quarters it ranged from $9.2M (Q2 2026) to $15.1M (Q1 2025).